|
Sign In to gain access to subscriptions and/or personal tools.
|
Integrative Cancer Therapies, Vol. 2, No. 4,
315-329 (2003)
DOI: 10.1177/1534735403259152
Insulin and Cancer
D. Barry Boyd, MD,MS
239 Glenville Road, Greenwich, CT 06831dbb{at}integrativeoncology.org
Obesity has recently been linked to mortality from the majority of cancers. The insulin/insulin-like growth factor (IGF) system may partly explain this effect. The metabolic syndrome, associated with hyperinsulinemia, may modulate this effect. Recent evidence supports the role of insulin and IGF-1 as important growth factors, acting through the tyrosine kinase growth factor cascade in enhancing tumor cell proliferation. In addition, the metabolic syndrome associated with a chronic inflammatory state and accompanying cytokine abnormalities may also contribute to tumor progression. Growing links between insulin and the etiology as well as prognosis in colon, prostate, pancreatic, and, particularly, breast cancer are reviewed. Of particular concern is the evidence that elevated IGF-1 may interfere with cancer therapy, adversely affecting prognosis. The role of insulin is of concern because of the increasing levels of obesity and the associated metabolic syndrome. Weight gain, through typical Western diet; limited levels of activity; and, more recently, stress-related changes in neuroendocrine function may lead to insulin resistance and hyperinsulinemia. The opportunity for a multidisciplinary approach involving nutrition, exercise, and stress reduction in an integrative setting may be crucial to limiting the insulin-resistant state and improving cancer outcomes.
Key Words: insulin • insulin-like growth factor 1 • obesity • metabolic syndrome • cancer
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Rodon, V. DeSantos, R. J. Ferry Jr., and R. Kurzrock
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials
Mol. Cancer Ther.,
September 1, 2008;
7(9):
2575 - 2588.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. W. Wong and D. J. A. Jenkins
Carbohydrate Digestibility and Metabolic Effects
J. Nutr.,
November 1, 2007;
137(11):
2539S - 2546S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yu, Y. Hao, and L. A. Feig
The R-Ras GTPase Mediates Cross Talk between Estrogen and Insulin Signaling in Breast Cancer Cells.
Mol. Cell. Biol.,
September 1, 2006;
26(17):
6372 - 6380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. McCarty and K. I. Block
Toward a core nutraceutical program for cancer management.
Integr Cancer Ther,
June 1, 2006;
5(2):
150 - 171.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. J. Goodwin, M. Ennis, I. G. Fantus, K. I. Pritchard, M. E. Trudeau, J. Koo, and N. Hood
Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer?
J. Clin. Oncol.,
September 1, 2005;
23(25):
6037 - 6042.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kline, W. Yu, and B. G. Sanders
Vitamin E and Breast Cancer
J. Nutr.,
December 1, 2004;
134(12):
3458S - 3462S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Daskalopoulou, D. P. Mikhailidis, and M. Elisaf
Prevention and Treatment of the Metabolic Syndrome
Angiology,
November 1, 2004;
55(6):
589 - 612.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. S. Daskalopoulou, D. P. Mikhailidis, and M. Elisaf
Prevention and Treatment of the Metabolic Syndrome
Angiology,
November 1, 2004;
55(6):
589 - 612.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. I. Block
Integrative Tumor Board: Glioblastoma Multiforme: Integrative Physician's Perspective
Integr Cancer Ther,
June 1, 2004;
3(2):
170 - 172.
[PDF]
|
|
|
|
|
|
|
K. I. Block
Integrative Tumor Board: Metastatic Renal Cell Carcinoma
Integr Cancer Ther,
March 1, 2004;
3(1):
44 - 46.
[PDF]
|
|
|
|
|
